梅拉斯综合征呈现与高伤心肌病和高级心力衰竭:一个多系统的诊断挑战
Jozef Dodulík1,2, Marie Lazárová1,2, Eva Kapsová1,2
1Department of Internal Medicine and Cardiology, University Hospital Ostrava, 708 00 Ostrava, Czech Republic.
Journal of clinical medicine
|February 13, 2026
概括
带有乳酸和中风类发作 (MELAS) 的线粒体脑膜病变可以表现为心肌病变. 早期的基因检测对于诊断这种罕见的疾病至关重要,特别是在和听力问题同时存在的情况下.
科学领域:
- 遗传学 是一个遗传学.
- 心脏病学 心脏病学
- 神经学 神经学
背景情况:
- 带有乳酸和中风类发作 (MELAS) 的线粒体脑膜异常是一种罕见的遗传性疾病.
- 心脏干扰,包括缩性心肌病和心力衰竭,在MELAS中经常被忽视.
- 在MT-TL1中,m.3243A>G变异是MELAS最常见的原因.
研究的目的:
- 突出考虑MELAS在不明原因心肌病的重要性.
- 强调基因检测在诊断MELAS中的作用.
- 为了说明MELAS与心脏表现的诊断挑战和管理.
主要方法:
- 一个43岁的男性患有慢性病和听力损失,并出现心力衰竭的病例报告.
- 诊断工作包括心声回声学,心脏MRI,冠状动脉血管学和全外体测序.
- 基因检测发现了m.3243A>G MT-TL1突变,证实了MELAS综合征.
主要成果:
- 患者出现了急性不补偿性心力衰竭和严重的左心室功能障碍.
- 心脏成像显示非缺血性心肌病与扩散性缩和纤维化.
- 整体外组测序证实了由于m.3243A>G突变导致的MELAS综合征.
结论:
- 无法解释的心肌病,特别是和听力缺陷,需要考虑线粒体疾病,如MELAS.
- 多模式评估和基因检测对于准确的诊断和管理至关重要.
- 及时诊断MELAS可以进行适当的心力衰竭治疗,并考虑先进的治疗方法,如心脏移植.
更多相关视频
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
4.3K
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
2.0K
相关概念视频
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
530
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
530
01:30Heart Failure IV: Classification and Diagnostic Evaluation
429
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
429
01:29Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
01:17Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
01:27Heart Failure I: Introduction
958
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
958
01:22Heart Failure VI: Adjunct Therapies
399
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
399